Sponsor Dossier
GM Pharma
Sponsor Dossier for GM Pharma. ARTG portfolio, PBS-listed brands, PBAC activity, AusPAR record — compiled by arcimedes.
- Brand: ACAMPROSATE-WGR
- Brand: ACARBOSE-WGR
- Brand: ACICLOVIR-WGR
- Brand: ALENDRONATE-WGR
- Brand: Allopurinol-WGR
- Brand: AMISULPRIDE-WGR
- Brand: AMITRIPTYLINE-WGR
- Brand: AMLODIPINE-WGR
About
GM Pharma is an Australian Private Company with ABN 19006286255, registered in Victoria. The entity is active.
Portfolio
GM Pharma has 145 brands on the ARTG, of which 112 are indexable and 110 carry a Product Information document. 94 brands are PBS-listed, 3 have a PBAC outcome on record, and 0 have an AusPAR on record. Notable brands include ACAMPROSATE-WGR, ACARBOSE-WGR, ACICLOVIR-WGR, ALENDRONATE-WGR, Allopurinol-WGR, AMISULPRIDE-WGR, AMITRIPTYLINE-WGR, AMLODIPINE-WGR, AMOXICILLIN-WGR, AMOXICILLIN/CLAVULANIC ACID-WGR, ANASTROZOLE-WGR, APIXABAN-WGR.
Therapeutic focus
— Cardiology: 40 brands — Psychiatry: 27 brands — Infectious Disease: 18 brands — Neurology: 13 brands — Endocrinology: 9 brands — Pain Management: 7 brands — Gastroenterology: 6 brands — Musculoskeletal: 6 brands — Reproductive Health: 5 brands — Oncology: 4 brands — Immunology: 3 brands — Ophthalmology: 3 brands — Dermatology: 2 brands — Renal: 1 brand — Hepatology: 1 brand
PBS footprint
94 brands are PBS-listed, with the latest PBS schedule date 2026-10-01.
Regulatory activity
The latest PBAC outcome is 2009-11-01, across 3 brands with a PBAC outcome on record.